The purpose of this study is to evaluate the efficacy and safety of 100 mg and 150 mg of DVS
SR, an extended release form of desvenlafaxine succinate, in comparison to placebo for the
treatment of Vasomotor Symptoms (VMS) associated with menopause in a population of
postmenopausal women.
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Female.
Montgomery, Alabama 36106, United States
Peoria, Arizona 85381, United States
Upland, California 91786, United States
Colorado Springs, Colorado 80910, United States
Brooksville, Florida 34613, United States
Inverness, Florida 34452, United States
Miami, Florida 33143, United States
New Port Richey, Florida 34652, United States
Ocala, Florida 34471, United States
St. Petersburg, Florida 33709, United States
Tampa, Florida 33606, United States
Decatur, Georgia 30033, United States
Savannah, Georgia 31406, United States
Boise, Idaho 83702, United States
Idaho Falls, Idaho 83404, United States
Overland Park, Kansas 66210, United States
Louisville, Kentucky 40291, United States
Portland, Maine 04102, United States
Rockville, Maryland 20852, United States
Billings, Montana 59102, United States
Las Vegas, Nevada 89146, United States
Albuquerque, New Mexico 87102, United States
Winston-Salem, North Carolina 27103, United States
Bismark, North Dakota 58501, United States
Fargo, North Dakota 58104, United States
Cincinnati, Ohio 45267-0457, United States
Eugene, Oregon 97401, United States
Erie, Pennsylvania 16502, United States
Philadelphia, Pennsylvania 19114, United States
Wexford, Pennsylvania 15090, United States
Hilton Head Island, South Carolina 29926, United States
Midvale, Utah 84047, United States
Norfolk, Virginia 23507, United States
Richmond, Virginia 23294, United States